Privately held Bayhill Therapeutics Inc. stands to gain more than $350 million, including $25 million up front in cash and equity, from biotech giant Genentech Inc. in exchange for the worldwide development and commercialization rights for BHT-3021, which is being investigated as an immunotherapy for Type I diabetes. (BioWorld Today) Read More
